KEY DETAILS
Investor's Business Daily reports that Lilly stock climbed 3.6% on Thursday and joined the Big Cap 20 best stocks list.
The New York Post reports that FDA inspectors found gross contamination, including mold and bug infestations, at two Chinese factories making GLP-1 drug components.
Vox.com reports that roughly two thirds of private employer health plans were covering GLP-1 medications for weight loss as of 2026.
Fox News reports that a Maryland man named Engel has sued Novo Nordisk, alleging it failed to adequately warn that Ozempic could cause vision loss.
financialexpress.com reports that Novo Nordisk forecasts 15-20% annual growth for GLP-1 drugs in India amid rising competition from cheaper versions.
Eli Lilly shares climbed 3.6% on Thursday, landing the company on Investor's Business Daily's Big Cap 20 best stocks list. The New York Post reports that FDA inspectors found mold and bug infestations at two Chinese factories making GLP-1 drug components. Fox News reports that a Maryland man named Engel has sued Novo Nordisk, alleging the company failed to warn that Ozempic could cause vision loss.
That climb helped push Lilly onto a list of stocks IBD flagged as top performers this week, with the outlet's headline crediting Lilly as leading 19 stocks to best stock lists. Investor's Business Daily also reported that BeOne Medicines jumped 6.4% the same day, landing a spot on the flagship IBD 50. The outlet noted that its top-performing stock lists had just been updated. There's also news today about where some GLP-1 ingredients are actually made.
Those FDA findings come from an inspection that the New York Post describes as showing gross contamination at two factories in China that make components for GLP-1 weight-loss drugs. According to the Post, citing Bloomberg, both facilities are run by compounding pharmacies that produce semaglutide and tirzepatide for black-market versions of the drugs not approved for sale by safety regulators. The Post reports that both companies were placed on the FDA's import list, meaning their products could be confiscated at the border. A separate report cited by the Post found that staff at Nanjing Chengong Pharmaceutical had been buying active ingredients from other factories and applying their own company's seal of approval without reviewing testing and safety documentation. Coverage questions are also in the news today.
Vox.com reports that as of 2026, roughly two thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity. The outlet also reports that at least 10 percent of employer plans currently covering GLP-1s for weight loss say they are likely to drop that coverage in 2027. Vox cites a separate report from the Massachusetts Health Policy Commission finding that the number of commercially insured people in the state taking a GLP-1 drug fell by 50 percent between 2025 and the first quarter of 2026 as private coverage began to decline. According to Vox, companies including PepsiCo, Starbucks, and Lowe's are reportedly eliminating or reducing their coverage, and an analysis from Blue Cross Blue Shield Kansas concluded that covering GLP-1s for weight loss raised average employee health costs by $7,000 in the first year and another $4,200 in the second. Legal challenges are making headlines too.
Fox News reports that a Maryland man named Engel has filed a lawsuit against Novo Nordisk, alleging the company failed to adequately warn patients and doctors about the potential risk of vision loss from Ozempic. According to Fox News, Engel says the drug caused total vision loss, leaving him legally blind. The outlet reports that Engel is among hundreds of patients currently pursuing legal action against makers of GLP-1 medications, including Ozempic and Wegovy, over claims that the drugs caused NAION. Fox News notes that Novo Nordisk disputes that the medication causes NAION, stating that the available evidence does not establish a causal relationship between semaglutide and the eye condition. And overseas, growth forecasts are in focus.
financialexpress.com reports that Novo Nordisk forecasts 15 to 20 percent annual growth for GLP-1 drugs in India amid rising competition from cheaper versions. The outlet says competition intensified after semaglutide's patent expired in March, allowing domestic drugmakers to introduce lower-cost alternatives. According to financialexpress.com, Novo Nordisk has submitted applications for higher-dose semaglutide formulations, including a 2 mg dose for diabetes and a 7.2 mg dose for obesity, both under regulatory evaluation. The outlet also reports that Novo's oral semaglutide pill, approved specifically for obesity in the US, became available there in January 2026.
You can find the full reporting behind today's items at Investor's Business Daily, the New York Post, Vox.com, Fox News, and financialexpress.com. Each outlet has more detail on these stories if you want to read further.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.